Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma

Author:

Tabari Azadeh12ORCID,Cox Meredith2,D’Amore Brian23,Mansur Arian2ORCID,Dabbara Harika4,Boland Genevieve23ORCID,Gee Michael S.12,Daye Dania12

Affiliation:

1. Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

2. Harvard Medical School, Boston, MA 02215, USA

3. Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

4. Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA 02118, USA

Abstract

Pretreatment LDH is a standard prognostic biomarker for advanced melanoma and is associated with response to ICI. We assessed the role of machine learning-based radiomics in predicting responses to ICI and in complementing LDH for prognostication of metastatic melanoma. From 2008–2022, 79 patients with 168 metastatic hepatic lesions were identified. All patients had arterial phase CT images 1-month prior to initiation of ICI. Response to ICI was assessed on follow-up CT at 3 months using RECIST criteria. A machine learning algorithm was developed using radiomics. Maximum relevance minimum redundancy (mRMR) was used to select features. ROC analysis and logistic regression analyses evaluated performance. Shapley additive explanations were used to identify the variables that are the most important in predicting a response. mRMR selection revealed 15 features that are associated with a response to ICI. The machine learning model combining both radiomics features and pretreatment LDH resulted in better performance for response prediction compared to models that included radiomics or LDH alone (AUC of 0.89 (95% CI: [0.76–0.99]) vs. 0.81 (95% CI: [0.65–0.94]) and 0.81 (95% CI: [0.72–0.91]), respectively). Using SHAP analysis, LDH and two GLSZM were the most predictive of the outcome. Pre-treatment CT radiomic features performed equally well to serum LDH in predicting treatment response.

Funder

RSNA Seed

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference48 articles.

1. National Cancer Institute Surveillance Epidemiology and End Results Program (2018, March 11). Cancer Statistics Cancer Stat Facts: Melanoma of the Skin, Available online: https://seer.cancer.gov/statfacts/html/melan.html.

2. (2023, March 13). Available online: https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html.

3. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N. Engl. J. Med.,2017

4. Pelizzari, G., Basile, D., Zago, S., Lisanti, C., Bartoletti, M., Bortot, L., Vitale, M.G., Fanotto, V., Barban, S., and Cinausero, M. (2019). Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker. Cancers, 11.

5. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma;Diem;Br. J. Cancer,2016

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3